Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial

Conclusions1 mg BAY 85-8501 OD had a favourable safety and tolerability profile when administered for 28 days to patients with non-CF BE. Further studies with a longer treatment duration are needed to evaluate the potential clinical efficacy in this study population.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research

Related Links:

Introduction Non-cystic fibrosis (CF) bronchiectasis ("bronchiectasis") is a chronic airway disease for which little data exist to inform treatment decisions. We sought to compare the risks of respiratory infections in chronic users of inhaled corticosteroids (ICSs) versus macrolide monotherapy. Methods We identified a cohort of US Medicare enrollees with a bronchiectasis diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification code 494.0 or 494.1) between 2006 and 2014, excluding CF. We defined chronic new use as the first ≥28-day prescription of ICS therapy or macrolide mon...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: CF and non-CF bronchiectasis Original Articles: Bronchiectasis Source Type: research
Pseudomonas aeruginosa is the most prevalent opportunistic pathogen in the airways of cystic fibrosis (CF) patients. The pulmonary disorder is characterized by recurrent microbial infections and an exaggerated host inflammatory immune response led primarily by influx of neutrophils. Under these conditions, chronic colonization with P. aeruginosa is associated with diminished pulmonary function and increased morbidity and mortality. P. aeruginosa has a wide array of genetic mechanisms that facilitate its persistent colonization of the airway despite extensive innate host immune responses. Loss of function mutations in the q...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Dysfunction of the pancreas is related to a number of diseases, most famously diabetes. Conditions such as cystic fibrosis-related diabetes (CFRD), are particularly difficult to study in a laboratory setting, but researchers at Cincinnati Children&rs...
Source: Medgadget - Category: Medical Devices Authors: Tags: Materials Medicine Source Type: blogs
The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group came together to consider these challenges and possible strategies to address them. Over the last 18  months, we have discussed internally and gathered views from a broad range of individuals representing patient organizations, clinical and research teams, the pharmaceutical industry and regulatory agencies. In this and the accompanying article, we discuss two main areas of focus: i) optimising t rial design and delivery for speed/efficie...
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Review Source Type: research
Conclusions Cystic fibrosis or CFTR-RD can present as ARP/CP. Complete diagnostic testing for CFTR-RD in patients with ARP/CP will broaden treatment options and help to identify comorbid illness.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
In people with and without Cystic Fibrosis (CF), does side lying during nebulisation change: the proportion of the dose loaded in the nebuliser that is deposited in the lungs; the uniformity of deposition thro...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Research article Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31310009 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Condition:   Cystic Fibrosis Intervention:   Device: Fitbit Tracker Sponsors:   Medical College of Wisconsin;   Cystic Fibrosis Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Intervention:   Behavioral: Motivational Interviewing Sponsors:   Belfast Health and Social Care Trust;   Queen's University, Belfast Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Intervention:   Device: Fitbit Tracker Sponsors:   Medical College of Wisconsin;   Cystic Fibrosis Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cystic Fibrosis | Drugs & Pharmacology | Respiratory Medicine | Study